• Policy Lab

    SIGNAL WATCHING: How Life Science Venture Capital Perceives Medicare Part D Reforms

    This report examines proposed changes to Part D from the lens of the early-stage life science research ecosystem.

  • Article

    Investors Want New Drugs for a Better World — and a Return on Their Money

    One truth stays constant: In the long run, H.R. 3 would hurt the very patients Democrats want to help. Here’s why.

  • Statement

    Incubate Statement on Introduction of the PASTEUR Act

    Incubate commends Senators Michael Bennet (D-CO) and Todd Young (R-IN) and Representatives Mike Doyle (D-PA) and Drew Ferguson (R-GA) for re-introducing the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act.

  • Article

    What M&A Critics Don’t Understand About Drug Innovation

    We want brilliant minds at thousands of small, unheard-of biotechs chasing tomorrow’s cures. But they can only do so if larger manufacturers help ensure their ideas are safe, effective, and actually reach patients.

  • Article

    As Washington Ties Pharma’s Hands, China Is Leaping Ahead

    American policy should be focused on protecting, rather than undermining, the global dominance of our biotechnology industry.

  • Video

  • Statement

    Incubate Raises Concern About President Biden’s Support of WTO TRIPS Waiver

    In response to the Biden Administration’s recent announcement that the U.S. will support waiving intellectual property protections for COVID-19 vaccines, the Executive Director of Incubate, John Stanford, issued the following statement

  • Statement

    Life Science Investors & Early Stage Ecosystem Raise Concern with Reintroduction of H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act

    Incubate strongly opposes HR 3, which was reintroduced today. The decision to pursue price controls is unfortunate. Moreover, the decision to propose this while the life sciences industry continues to drive health and economic recovery amid a pandemic is unfathomable.

  • Article

    CBO Report: Research and Development in the Pharmaceutical Industry

    CBO assesses trends in spending for prescription drug research and development (R&D) and the introduction of new prescription drugs. CBO...